CPC C07K 16/2878 (2013.01) [A61K 39/001111 (2018.08); A61K 39/001117 (2018.08); A61P 35/00 (2018.01); A61K 2039/507 (2013.01); C07K 2317/565 (2013.01); C07K 2317/75 (2013.01); C07K 2317/92 (2013.01)] | 28 Claims |
1. A method for treating cancer in a subject, the method comprising: administering to the subject an effective amount of:
(i) an isolated agonistic monoclonal antibody that specifically binds to human CD137 with an affinity (KD) of about 30-100 nM, or that binds to an epitope on human CD137 comprising K114 of SEQ ID NO: 3, or both, or an antigen-binding fragment thereof; and
(ii) a PD-1 antagonist,
wherein the agonistic monoclonal antibody or antigen-binding fragment thereof is administered to the subject prior to administration of the PD-1 antagonist, thereby treating the subject, and
wherein the isolated agonistic monoclonal antibody or antigen-binding fragment thereof comprises heavy and light chain CDRs comprising heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 48, 56 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 69, 78 and 89, respectively.
|